Scott Gabler, MD
Nuclear Cardiology · Voorhees, NJNPI 1972652840
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,060 of the $7,464 with a category attached, or 67.8%. 29 manufacturers reported payments, led by Abbott at 47.8% of the total. Reporting peaked in 2024 at $2,532 and has fallen 65.9% since, to $864 in 2025.
Across 193 payments — averaging $38.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$442
- Edwards Lifesciences$423
- Boehringer Ingelheim$398
- Amgen$384
- Atricure, Inc.$342
- plus $2K from 23 others
Across 19 payments — averaging $3477.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$65K
- Novartis$700
What the payments were for
- Travel & lodging$2,40432%
- Food & beverage$5,06068%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $3,569 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $442 |
| Edwards Lifesciences | 6 | $423 |
| Boehringer Ingelheim | 12 | $398 |
| Amgen | 24 | $384 |
| Atricure, Inc. | 4 | $342 |
| Novartis | 20 | $317 |
| Heartflow, Inc. | 4 | $299 |
| Abiomed | 4 | $297 |
| AstraZeneca | 10 | $148 |
| Johnson & Johnson | 9 | $142 |
| Pfizer | 7 | $113 |
| Merck | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Boston Scientific | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 4 | $57 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $41 |
| BD | 1 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Cvrx, Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,464 in reported general payments places this provider in the 75th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 763 | $976,845 |
| Repatha SureclickEvolocumab | 152 | $226,917 |
| XareltoRivaroxaban | 155 | $212,632 |
| EntrestoSacubitril/Valsartan | 114 | $181,936 |
| FarxigaDapagliflozin Propanediol | 78 | $76,267 |
| Praluent PenAlirocumab | 50 | $64,487 |
| JardianceEmpagliflozin | 38 | $51,442 |
| Icosapent Ethyl | 47 | $28,400 |
| Atorvastatin Calcium | 1,263 | $15,866 |
| VascepaIcosapent Ethyl | 23 | $15,860 |
| Metoprolol Succinate | 780 | $12,406 |
| Ezetimibe | 416 | $12,288 |
| BrilintaTicagrelor | 17 | $11,881 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 186 | $7,744 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $6,635 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $113 | $976,845763 claims |
| Johnson & JohnsonXarelto | $142 | $212,632155 claims |
| NovartisEntresto | $317 | $181,936114 claims |
| AstraZenecaFarxiga, Brilinta | $148 | $88,14795 claims |
| Boehringer IngelheimJardiance | $398 | $51,44238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Voorhees
- David SchlesselVoorhees$2K
- Stephen CrawfordVoorhees$1K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$28K
- Hafeza ShaikhWillingboro$16K
- Nasser ChaudhryCherry Hill$11K
- Ralph RussoMoorestown$11K
- Anthony SauerweinMoorestown$10K
- Howard WeinbergSewell$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.